it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done.. november 2016 (25)... all sections
biohaven: "rimegepant pivotal phase 3 trial results -- conference call.".
helen was proud and extremely independent, but had a soft, elegant side to her... september 2013 (21).the software identified and measured a marker of svd and then gave a score indicating how severe the disease was ranging from mild to severe.. ..however, bentley also warned that these treatments can be hazardous as they may cause bleeding which becomes more likely as the amount of svd increases..